Verici Dx plc
Market Cap
$8.55M
P/E Ratio
-0.28
EPS
$-0.02
Dividend Yield
0.00%
52-Week Range
$0.47 — $3.50
Volume
584.24K
Avg Volume
1.22M
Beta
1.51
P/E (TTM)
-0.28
Forward P/E
—
PEG Ratio
0.02
P/S (TTM)
8.00
P/B (TTM)
0.76
P/FCF
—
EV/EBITDA
—
EV/Sales
—
ROE (TTM)
-1.78%
ROA (TTM)
-1.52%
ROIC
—
Gross Margin
1.06%
Operating Margin
-4.73%
Net Margin
—
Debt/Equity
0.11
Current Ratio
0.91
EPS Growth (YoY)
—
Revenue Growth (YoY)
—
EPS Growth (3Y)
+0.20%
EPS Growth (5Y)
+0.17%
Sales Growth (3Y)
+0.77%
Sales Growth (5Y)
+0.46%
EPS Est (This Year)
—
EPS Est (Next Year)
—
Dividend Yield
—
Annual Dividend
—
Payout Ratio
—
Frequency
—
Ex-Dividend Date
—
Cash/Share
$0.00
Institutional %
—
Inst. Net Change
—
Insider Net Shares (90d)
—
Outstanding Shares
1.51B
Float
234.68M
Free Float %
15.51%
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Country
GB
Exchange
LSE
IPO Date
2020-11-03
Employees
19
CEO
Sara jane Barrington
Index Membership
—
Website
https://www.vericidx.com
Verici Dx plc (VRCI.L) is a healthcare company in the medical - diagnostics & research industry listed on the LSE. With a market capitalization of $8.55M, a P/E ratio of -0.28, VRCI.L is tracked by stockscreenr alongside 25,000+ other tickers. Use the free stock screener to compare VRCI.L against other stocks using dozens of fundamental and technical filters.
Verici Dx plc (VRCI.L) has a trailing twelve-month (TTM) P/E ratio of -0.28. This is below the market average, which may suggest the stock is undervalued or has lower growth expectations. The P/E ratio measures how much investors are willing to pay per dollar of earnings.
No, Verici Dx plc (VRCI.L) does not currently pay a regular dividend. The company may be reinvesting profits into growth, research, or debt reduction instead of returning cash to shareholders through dividends.
Verici Dx plc (VRCI.L) has a market capitalization of $8.55 million, classifying it as a micro-cap company. Market cap is calculated by multiplying the current share price by the total number of outstanding shares.